Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Gastrointestinal 1CNS 1

Conditions

Leukemia, Myeloid, Acute 6Leukemia 2Myelodysplastic Syndromes 1Leukemia, Myeloid 1Immunoblastic Lymphadenopathy 1Hematologic Neoplasms 1Glioma 1Chondrosarcoma 1Cholangiocarcinoma 1

Interventions

Gemcitabine 210-propargyl-10-deazaaminopterin 2tislelizumab 1ontuxizumab 1glofitamab 1enasidenib 1duvelisib 1brincidofovir 1belinostat 1WW Domain-Containing Oxidoreductase 1Vitamin B 12 1Sensitivity and Specificity 1MLN 8237 1MAC-ST-001 1Folic Acid 1Fentanyl 1Fenretinide 1Commerce 1Bendamustine Hydrochloride 1(N(1),N(12))bis(ethyl)-6,7-dehydrospermine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Immunoblastic Lymphadenopathy × enasidenib × Clear all
NCT02273739 2021-02-23

Study of Orally Administered Enasidenib (AG-221) in Adults With Advanced Solid Tumors, Including Glioma, or Angioimmunoblastic T-cell Lymphoma, With an IDH2 Mutation

Celgene

Phase 1/2 Completed
21 enrolled 33 charts
CNSGastrointestinalSarcoma

Chondrosarcoma, Glioma, Immunoblastic Lymphadenopathy, Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡